Literature DB >> 27741089

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Siri Tähtinen1, Carolin Blattner, Markus Vähä-Koskela, Dipongkor Saha, Mikko Siurala, Suvi Parviainen, Jochen Utikal, Anna Kanerva, Viktor Umansky, Akseli Hemminki.   

Abstract

The immunosuppressive microenvironment of solid tumors renders adoptively transferred T cells hypofunctional. However, adenoviral delivery of immunostimulatory cytokines IL2 and TNFα can significantly improve the efficacy of adoptive T-cell therapy. Using ret transgenic mice that spontaneously develop skin malignant melanoma, we analyzed the mechanism of action of adenoviruses coding for IL2 and TNFα in combination with adoptive transfer of TCR-transgenic TRP-2-specific T cells. Following T-cell therapy and intratumoral virus injection, a significant increase in antigen-experienced, tumor-reactive PD-1 CD8 T cells was seen in both cutaneous lesions and in metastatic lymph nodes. A reverse correlation between tumor weight and the number of tumor-reactive PD-1 tumor-infiltrating lymphocytes (TILs) was observed, suggesting that these T cells could target and kill tumor cells. It is interesting to note that, local expression of cytokines did not affect intratumoral levels of T-regulatory cells (Tregs), which had previously been associated with systemic IL2 therapy. Instead, Ad5-IL2 induced upregulation of IL2 receptor α-chain (CD25) on conventional CD4CD25Foxp3 cells, indicating that these CD4 T cells may contribute to CD8 T-cell activation and/or homing. Signs of therapy-induced resistance were also observed as the expression of PD-L1 on tumor-infiltrating granulocytic myeloid-derived suppressor cells was upregulated as a reaction to PD-1+ TILs. Finally, beneficial ratios between tumor-reactive PD-1 CD8 TILs and immunosuppressive cell subsets (Tregs and nitric oxide-producing myeloid-derived suppressor cells) were observed in primary and secondary tumor sites, indicating that local delivery of IL2 and TNFα coding adenoviruses can systemically modify the cellular composition of the tumor microenvironment in favor of adoptively transferred T cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27741089     DOI: 10.1097/CJI.0000000000000144

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  11 in total

1.  TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Authors:  V Cervera-Carrascon; M Siurala; J M Santos; R Havunen; S Tähtinen; P Karell; S Sorsa; A Kanerva; A Hemminki
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

2.  Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Authors:  João Manuel Santos; Víctor Cervera-Carrascon; Riikka Havunen; Sadia Zafar; Mikko Siurala; Suvi Sorsa; Marjukka Anttila; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2018-07-13       Impact factor: 11.454

3.  Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.

Authors:  Riikka Havunen; Mikko Siurala; Suvi Sorsa; Susanna Grönberg-Vähä-Koskela; Michael Behr; Siri Tähtinen; João Manuel Santos; Pauliina Karell; Juuso Rusanen; Dirk M Nettelbeck; Anja Ehrhardt; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2016-12-31       Impact factor: 7.200

Review 4.  Tumor-related interleukins: old validated targets for new anti-cancer drug development.

Authors:  Sarra Setrerrahmane; Hanmei Xu
Journal:  Mol Cancer       Date:  2017-09-19       Impact factor: 27.401

Review 5.  Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.

Authors:  Hong-My Nguyen; Kirsten Guz-Montgomery; Dipongkor Saha
Journal:  Cells       Date:  2020-02-10       Impact factor: 6.600

Review 6.  Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.

Authors:  Weiyue Ban; Jianhuan Guan; Hanwei Huang; Zhonggui He; Mengchi Sun; Funan Liu; Jin Sun
Journal:  Nano Res       Date:  2022-02-14       Impact factor: 10.269

7.  Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.

Authors:  James H A Clubb; Tatiana V Kudling; Camilla Heiniö; Saru Basnet; Santeri Pakola; Víctor Cervera Carrascón; João Manuel Santos; Dafne C A Quixabeira; Riikka Havunen; Suvi Sorsa; Vincent Zheng; Tuula Salo; Leif Bäck; Katri Aro; Sanni Tulokas; Venla Loimu; Akseli Hemminki
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

Review 8.  Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste".

Authors:  Robert Hester; Pawel K Mazur; Florencia McAllister
Journal:  Clin Cancer Res       Date:  2021-06-30       Impact factor: 12.531

Review 9.  Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.

Authors:  Yuhui Yang; Chunyan Li; Tao Liu; Xiaofang Dai; Alexandr V Bazhin
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

10.  Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.

Authors:  João Manuel Santos; Camilla Heiniö; Victor Cervera-Carrascon; Dafne C A Quixabeira; Mikko Siurala; Riikka Havunen; Ralf Butzow; Sadia Zafar; Tanja de Gruijl; Heini Lassus; Anna Kanerva; Akseli Hemminki
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.